Azenta (NASDAQ:AZTA – Get Free Report) and CryoPort (NASDAQ:CYRX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Azenta and CryoPort, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 1 | 2 | 4 | 0 | 2.43 |
| CryoPort | 0 | 2 | 8 | 0 | 2.80 |
Azenta presently has a consensus target price of $41.20, suggesting a potential upside of 12.88%. CryoPort has a consensus target price of $19.33, suggesting a potential upside of 7.53%. Given Azenta’s higher probable upside, research analysts clearly believe Azenta is more favorable than CryoPort.
Earnings & Valuation
This table compares Azenta and CryoPort”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Azenta | $593.82 million | 2.69 | -$55.76 million | ($2.76) | -13.22 |
| CryoPort | $176.18 million | 5.17 | $78.30 million | ($0.90) | -19.98 |
CryoPort has lower revenue, but higher earnings than Azenta. CryoPort is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Azenta and CryoPort’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -20.63% | 1.18% | 0.97% |
| CryoPort | -20.05% | -7.20% | -4.30% |
Volatility & Risk
Azenta has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.
Institutional & Insider Ownership
99.1% of Azenta shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 10.9% of Azenta shares are owned by insiders. Comparatively, 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
About CryoPort
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
